MAPT and Alzheimer disease: Classical AD-biomarkers such as CSF Aβ1−42, total-tau (t-tau), and phosphorylated-tau (p-tau) are well-documented within the literature as being able to distinguish between AD and cognitively normal (CN) individuals [12].